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Esophageal cancera b s t r a c t
miR-625 has been reported to exhibit abnormal expression in esophageal cancer (EC), but the mech-
anism and functions of miR-625 in esophageal cancer remain unclear. miR-625 down-regulation
and Sox2 up-regulation were validated by qRT-PCR in 158 EC samples. Low expression of miR-625
promotes cell proliferation and invasion, while high expression of miR-625 has the opposite effect.
Sox2, a target gene of miR-625, was examined by luciferase assay and western blot. Our data suggest
that miR-625 may regulate the biological processes of EC via controlling Sox2 expression.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Esophageal cancer (EC) is one of malignant cancers worldwide
and the common cause of cancer death. Esophageal cancer con-
tains two histological types, esophageal squamous cell carcinoma
(ESCC) and esophageal adenocarcinoma (EAC) [1]. In China, a high
incidence of ESCC exceeds 100 cases per 100000 people per year. In
contrast, esophageal adenocarcinoma (EAC) is the incidence of AC
has increased steeply in Western countries [2]. Despite the rapid
advancement in diagnosis and therapy for EC, the average 5-year
overall survival has remained at 10–20% because of the prolifera-
tion and invasion of cancer cells [3]. Therefore, elucidating the
potential mechanism of tumor development would help us
understand the progression and the therapy of EC.
microRNAs (miRNAs) were identiﬁed as an abundant class of
small non-coding RNAs that played an important role in post-tran-
scriptional regulation in different biological processes [4–6]. Here,
functions of miR-625 related to cancers have been shown in recent
studies. For example, decreased expression of microRNA-625 is
associated with tumor metastasis and poor prognosis in patientswith colorectal cancer [7]. Down-regulated miR-625 suppresses
invasion and metastasis of gastric cancer by targeting ILK [8].
SRY (sex determining region Y)-box 2, also known as Sox2, is
one of the crucial transcriptional factors that control the unique
properties of stem cells self-renewal and pluripotency and play a
critical role in maintaining the stem cell-like phenotype in cancer
cells [9,10]. Recently, a number of studies have reported the contri-
bution of Sox2 to tumorigenesis and tumor progression and metas-
tasis of various types of tumors, including lung cancer [11,12],
breast cancer [13,14], esophageal cancer [15] and ovarian cancer
[16].
In our study, we detected the expression of miR-625 in esoph-
ageal cancer and found that miR-625 was related to tumor depth,
stage, and metastasis of esophageal cancer. Furthermore, we iden-
tiﬁed that miR-625 could regulate the proliferation and invasion of
EC cells by targeting Sox2.
2. Material and methods
2.1. Clinical samples
A total of 158 patients with esophageal cancer had undergone
routine surgery at Afﬁliated Hospital of Jiangnan University from
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corresponding adjacent esophageal tissues taken from the 158 pa-
tients were collected, immediately snap frozen in liquid nitrogen,
and stored at 80 C until RNA extraction. This study was ap-
proved by the Ethical Committee of Afﬁliated Hospital of Jiangnan
University, and every patient had written informed consent.
2.2. Cell culture
Eca-109 and TE-1 cell lines (ATCC) was employed for the pres-
ent study and was cultured in RPMI-1640 medium with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA) and penicillin (100 U/ml).
Cells were cultured at 37 C with 5% CO2.
2.3. Isolation of total RNA and quantitative RT-PCR
Total RNA was extracted from collected tissues using TRIzol
(Invitrogen, USA) and then both miRNA and mRNA were reversely
transcribed to cDNA. The expression levels of miRNAs were as-
sessed by the TaqMan stem-loop RT-PCR method with a mirVana
miRNA Detection Kit and gene-speciﬁc primers. U6 small nuclear
RNA was used for normalization. Relative expression levels of
Sox2 mRNA were examined by SYBR Green real-time PCR (RT-
PCR) and normalized to GAPDH. Primers of Sox2 for qRT-PCR were
as follows: forward, 50-CAC ATG AAG GAG CAC CCG GAT TAT-30; re-
verse 50-GTTCATGTGCGCGTAACTGTCCAT-30. Primers of GAPDH
were as follows: forward, 50-CGTGGGCCGCCCTAGGCACCA-30 and
reverse, 50-TTGGCTTAGGGTTCAGGGGGG-30. RT-PCR was per-
formed by using the ABI 7500 Fast Real-Time PCR system (ABI,
CA, USA).
2.4. Cell proliferation assay
Cells were seeded into 96-well plates at 2000 cells/well. 20 lL
of 3-(4, 5)-dimethylthiahiazo (-z-y1)-3, 5-di-phenytetrazoliumro-
mide (MTT) (0.5 mg/mL) was added into each well. Finally,
200 lL of DMSO was added to each well to dissolve the precipitate.
Optical density was measured at the wavelength of 490 nm. The
data are presented as mean ± SEM, derived from triplicate samples
of at least 3 independent experiments.
2.5. Apoptosis assay
Twelve-four hours after transfection, then all cells were treated
by carboplatin with concentration 40 lg/ml from Qilu pharmaceu-
tical Co., Ltd. Apoptosis in cultured cells was evaluated using an-
nexin V labeling. An annexin V–APC labeled Apoptosis Detection
Kit (Abcam) was used according to the manufacturer’s protocol.
2.6. Transwell assay
Cell motility was measured using an 8-lm-pore polycarbonate
membrane Boyden chamber insert in a Transwell apparatus (Mil-
lipore, MA, USA). The transfected cells were treated with trypsin/
EDTA solution, washed once with serum-containing RPMI-1640
medium. A total of 1 105 cells in 0.2 ml serum-free RPMI-1640
medium were seeded on a Transwell apparatus. RPMI-1640 con-
taining 10% FBS (600 ll) was added to the lower chamber. An
invasion assay was conducted following the same procedure,
with the exception that the ﬁlters of the transwell chambers
were coated with 45 lg Matrigel (BD Biosciences; San Jose, CA,
USA). Following incubation of the cells for 24 h at 37 C in a 5%
CO2 incubator, cells on the top surface of the insert were
removed by wiping with a cotton swab. Cells that invaded to
the bottom surface of the insert were ﬁxed in the 100% precoolingmethanol for 10 min, stained in 0.5% crystal violet for 30 min,
then rinsed in PBS and subjected to microscopic inspection. The
values for invasion were obtained by counting three ﬁelds per
membrane and represented the average of three independent
experiments.
2.7. Western blot
Total proteins were prepared from the established cells, quanti-
ties using a protein assay (BCA method, Beyotime, China). Proteins
were fractionated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS–PAGE) transferred to polyvinylidene ﬂuoride
(PVDF) membrane, blocked in 5% dry milk at room temperature for
1 h and immunostained with antibodies at 4 C overnight using
anti-Sox2 (1:500, santa, USA) and anti-GAPDH (1:5000, kangcheng,
China). All results were visualized through a chemiluminescent
detection system (Pierce ECL Substrate Western blot detection sys-
tem, Thermo, Pittsburgh, PA) and then exposed in Molecular Ima-
ger ChemiDoc XRS System (Bio-Rad, Hercules, CA). The integrated
density of the band was quantiﬁed by Image software.
2.8. Transient transfection
Oligonucleotides hsa-miR-625 mimics (miR-625), NC (miR-
control), hsa-miR-625 inhibitors (anti-miR-625), inhibitor NC
(anti-miR-control) were purchased from GenePharma (Shanghai,
PR China). Transfection of cells with oligonucleotides was performed
using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA)
at a ﬁnal concentration of 100 nM. Transfection efﬁciency was
monitored by qRT-PCR.
2.9. Plasmid construction and cell transduction
30-UTR sequence of Sox2 which was predicted to interact with
miR-625 or a mutant sequence with the predicted target sites
was inserted into the KpnI and SacI sites of pGL3 promoter vector
(Genscript, Nanjing, China). They were named pGL3-Sox2 and
pGL3-Sox2-mut. The cells were plated onto 6-well plates and were
transfected with 100 ng of pGL3-Sox2 or pGL3-Sox2-mut, and miR-
625 mimics (50 nM) by using Lipofectamine 2000 (Invitrogen
Corp., CA, USA). Sox2 gene was synthesized (purchased from Gen-
script, Piscataway, NJ) with restrictive digestion using Mlu I and
subcloned pLV-GFP plasmid (gift from D. Beicheng Sun, University
of Nanjing Medical University, China), and named pLV-GFP-Sox2.
Recombinant lentivirus was generated from 293T cells using cal-
cium phosphate precipitation. Cell lines were transfected with len-
tivirus using polybrene (8 lg/ml).
2.10. Luciferase activities analysis
48 h after transfection, luciferase actions were measured in Vic-
tor 1420 Multilabel Counter (Wallac, Finland) using Luciferase As-
say System (Promega, USA) according to the manufacturer’s
protocol.
2.11. Statistical methods
Themethod of 2DCt was used to analyze the results of RT-PCR in all
the experiments performed in this study. Statistical analysis was per-
formed using STATA 11, and presentedwithGraph PADprism software.
The results obtained from experiment in vitro assays are presented as
mean ± SEM from ﬁve separate experiments in triplicates per experi-
ment, and the data was analyzed byWilcoxon rank-sum (Mann–Whit-
ney) test. Results were considered statistically signiﬁcant at P < 0.05.
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3.1. miR-625 was decreased in human esophageal cancer tissues
The expression of miR-625 was analyzed in 158 EC samples and
corresponding adjacent tissues by qRT-PCR. Signiﬁcantly, miR-625
expression was lower in EC tissues than corresponding adjacent
tissues (P = 0.0009) (Fig. 1A). All EC were divided into miR-625
low-expression group (n = 89) and high-expression group
(n = 69), median was used as cut off. The correlation between
miR-625 expression and clinicopathological characteristics is
exhibited (Table 1). No positive correlation with gender, age, histo-
logical differentiation, however, there was signiﬁcantly correlation
with tumor depth (P = 0.002), tumor stage (P = 0.003) and metasta-
sis (P = 0.002). The aberrant expression level of miR-625 suggested
that miR-625 might play an important role in EC development.
Therefore, based on this expression pattern, we chose the Eca-
109 and TE-1 esophageal cancer cell lines to verify the effect of
miR-625.
3.2. Aberrant expression level of miR-625 affected EC cell invasion
in vitro
Previous studies have shown that miR-625 is downregulated in
EC by using microarray [17], but the roles of miR-625 have not
been elucidated. In this study, Eca-109 and TE-1 cell lines were
transfected with miR-625 mimics, NC, miR-625 inhibitor and
inhibitor NC, respectively. The transfection efﬁciency was vali-
dated by qRT-PCR (Fig. 1C). Matrigel invasion assay showed that
overexpression of miR-625 attenuated Eca-109 and TE-1 cell lines
invasion, whereas the suppressed miR-625 promoted the invasionFig. 1. miR-625 is down-regulated and Sox2 is up-regulated in EC patients. (A) The exp
relative to U6 were determined by qRT-PCR. (n = 158, P < 0.05). (B) The mRNA levels of So
evaluated by qRT-PCR. (C) miR-625 expression level in cell lines transfected with miR-62
inhibitor (inhibitor NC). The result was validated by real-time PCR. Data are representedability of EC cell lines (Fig. 2). The results suggested that miR-625
may play an important role in inhibiting EC metastasis.
3.3. miR-625 inhibited cell proliferation but had no effect on cell
apoptosis
To investigate whether miR-625 could regulate EC cell lines
proliferation in vitro, the effect of miR-625 on cell proliferation
was detected by using MTT assay. The assay showed that the cell
survival of cells transfected with miR-625 mimics in cell lines
was signiﬁcantly less than the controls. Meanwhile, the cell sur-
vival of cells transfected with miR-625 inhibitor in cell lines was
more than the controls (Fig. 3A and B). We also used apoptosis as-
say to detect the effect of miR-625 on cell apoptosis.
To further identify the role of miR-625 in carboplatin-induced
apoptosis, we explored the regulatory mechanism through which
miR-625 confers to carboplatin-mediated apoptosis. However,
there was no obvious difference (Fig. 3C and D). These data indi-
cated that miR-625 could inhibit cell proliferation but have no ef-
fect on cell apoptosis in vitro.
3.4. Decreased expression of miR-625 enhanced Sox2 expression in EC
cells
Among hundreds of genes predicted by online miRNA target
prediction algorithms, named microRNA.org (http://www.microrna.
org/microrna/), miRDB (http://mirdb.org/cgi-bin/), and DIANA-
MICROT (http://diana.cslab.ece.ntua.gr/micro-CDS/), we focused on
Sox2, which had been reported regulating esophageal cancer pro-
gression. Sox2 promotes tumor growth of esophageal squamous
cell carcinoma through the AKT/mammalian target of rapamycinression levels of miR-625 in human EC tissues and corresponding adjacent tissues
x2 relative to GAPDH in human EC tissues and corresponding adjacent tissues were
5 mimics, miR-625 inhibitor, control for miR-mimics (NC) and control for miR-625
as mean ± SEM. ⁄Indicates P < 0.05.
Table 1
Expression levels of miR-625 and Sox2 in EC and corresponding adjacent tissues.
Characteristics All Patients MiR-625 low expression MiR-625 high expression P Sox2 low expression Sox2 high expression P
n 158 89 69 70 88
Age (yr) 0.702 0.592
<64 82 45 37 38 44
P64 76 44 32 32 44
Sex 0.873 0.200
Male 79 45 34 31 48
Female 79 44 35 39 40
Histology 0.673 0.210
Adenocarcinoma 68 37 31 34 34
Suqamous cell carcinoma 90 52 38 36 54
Tumor depth 0.002** 0.022*
Tis, T1 72 31 41 39 33
T2, T3, T4 86 58 28 31 55
Stage 0.003** 0.018*
0, I 73 32 41 25 48
II, III, IV 85 57 28 45 40
Metastasis 0.002** 0.000**
Yes 108 70 38 59 49
No 50 19 31 11 39
* Indicates P < 0.05.
** Indicates P < 0.01.
Fig. 2. Effects of miR-625 expression on invasion of cell lines. Transwell assay was performed as described in Section 2. Cells were treated with miR-625 mimics, miR-625
inhibitor, NC and inhibitor NC for 24 h. The representative images of invasive cells at the bottom of the membrane stained with crystal violet were visualized as shown. The
quantiﬁcations of cell invasion were presented as percentage of cell numbers. All experiments were performed in triplicate and presented as mean ± SEM. ⁄Indicates
signiﬁcant difference compared with control group (P < 0.05). Every independent experiment was performed 3 times.
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esophageal cancer tissues (n = 158) by using qRT-PCR (Fig. 1B).
We also discovered that Sox2 expression was signiﬁcantly associ-
ated with tumor depth, metastasis and stage (P < 0.05; Table 1)
by using qRT-PCR. We detected the expression of Sox2 responses
to the changes of miR-625 expression in vitro. Western blot assays
showed that over-expressed miR-625 could signiﬁcantly down-
regulate expression level of Sox2, meanwhile, suppressed miR-
625 had adverse effects both in Eca-109 and TE-1 (Fig. 4B and C).
These data suggested that miR-625 could regulate expression of
Sox2 in EC cells.3.5. Sox2 was a direct target gene of miR-625
To further explore the role of miR-625 on controlling Sox2
expression, we cloned the 30-UTR fragment containing the pre-
dicted site into pGL3 luciferase reporter vector (pGL3-Sox2)
according to results of prediction. The 30-UTR fragment with mutant
sequence was also cloned as a control group (pGL3-Sox2-mut) in
the predicted target site. The results showed that the luciferase
activity decreased in Eca-109 cells with miR-625 mimics and
pGL3-Sox2 vectors. However, miR-625 mimics did not have any
effect on luciferase activity when target cells were transfected with
Fig. 3. Effection on cell lines proliferation and apoptosis. (A) (TE-1) and (B) (Eca-109): Absorbance at 490 nm was presented with Mean ± SEM. (C) (TE-1) and (D) (Eca-109):
Flow cytometry assay was performed to assess cell apoptosis.
Fig. 4. Effect of miR-625 on Sox2 expression. (A) The potential miR-625 seed region at the 30-UTR of Sox2 mRNA was computationally predicted by microRNA.org. Eca-109
cells were co-transfected with miR-625 mimics (or NC) with pGL3-Sox2 (or pGL3-Sox2-mut) vector. Luciferase activity was normalized by the ratio of ﬁreﬂy and Renilla
luciferase signals. (B) Sox2 protein expression levels in cell lines transfected with miR-625 mimics, miR-625 inhibitor, NC and inhibitor NC were analyzed by Western-
blotting. GAPDH was used as a loading control. Average values of integrated optical density (IOD) were assessed by analyzing ﬁve ﬁelds per slide and recorded in the
histogram. Data are represented as mean ± SEM. ⁄Indicates P < 0.05.
Z. Wang et al. / FEBS Letters 588 (2014) 915–921 919pGL3-Sox2-mut vector (Fig. 4A). These data suggested that Sox2
gene was one of the direct targets of miR-625.
3.6. Expression of Sox2 reversed the miR-625-induced inhibition
of cellular invasion and proliferation
Western blotting showed that co-transfection of miR-625 mim-
ics and Sox2 lacking the 30 UTR sequence (pcDNA3.1- Sox2) led toan increase in Sox2 expression, and abrogated the effects of miR-
625 mimics (Fig. 5A). In the transwell assays, co-transfection of
pcDNA3.1-Sox2 and miR-625 mimics increased the average num-
ber of invasion cells (P < 0.05; Fig. 5B). In the MTT assay, co-trans-
fection of pcDNA3.1-Sox2 and miR-625 mimics increased the
average number of proliferation cells (P < 0.05; Fig. 5C). These re-
sults suggest that Sox2 expression restores the anti-invasion and
anti-proliferation function of miR-625.
Fig. 5. Expression of Sox2 abrogates the anti-invasion and anti-proliferation functions of miR-625. (A) Transfection with pcDNA3.1-Sox2 and the miR-625 mimics increased
Sox2 expression. (B) Transfection with pcDNA3.1-Sox2 and the miR-625 mimics increased the average number of invasion cells. (C) Transfection with pcDNA3.1-Sox2 and the
miR-625 mimics increased the average number of proliferation cells. ⁄Indicates P < 0.05.
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In recent years, microRNAs (miRNAs) have been shown to have
critical regulatory roles in cancer biology [18–20]. Speciﬁcally for
EC, it is already reported that miRNAs contributes to proliferation
and invasion [21,22]. MicroRNA-21 (miR-21) post-transcription-
ally downregulates tumor suppressor Pdcd4 and stimulates
invasion, intravasation and metastasis in colorectal cancer [23].
MiR-139 inhibits invasion and metastasis of colorectal cancer by
targeting the type I insulin-like growth factor receptor [24].
MicroRNA-221 promotes colorectal cancer cell invasion and metas-
tasis by targeting RECK [25]. Here, we sought to provide evidence
for downexpression of miR-625 targeting of Sox2 to promote
proliferation and invasion in EC.
miR-625 expression is decreased in EC, but the underlying
mechanism of it and development in EC was unexplored. Down-
regulated miR-625 suppresses invasion and metastasis of gastric
cancer by targeting ILK. Decreased expression of microRNA-625
is associated with tumor metastasis and poor prognosis in patients
with colorectal cancer. Meanwhile, Sox2 expression is increased in
EC. Sox2 has been identiﬁed as an oncogene in many malignant
diseases. Sox2 regulates apoptosis through MAP4K4-Survivin sig-
naling pathway in human lung cancer cells [26]. The emerging role
of Sox2 in cell proliferation and survival by eliciting oncogenic
EGFR and BCL2L1 signaling with potential applications as a prog-
nosis marker and a therapeutic target in lung cancer [27]. Aberrant
Sox2 expression has been linked to development, progression, and
prognosis of multiple tumors by regulation of various cell signaling
pathways. Epithelial-to-mesenchymal transition (EMT) is consid-
erate to be involved in migration, tumor invasion and dissemina-
tion [28–30]. Sox2 promotes tumor metastasis by stimulating
epithelial-to-mesenchymal transition via regulation of WNT/b-
catenin signal network [31]. Sox2 promotes tumor growth ofesophageal squamous cell carcinoma through the AKT/mammalian
target of rapamycin complex 1 signaling pathway [32].
In this study, expression of miR-625 in EC specimens was signif-
icantly lower than in corresponding adjacent tissues. Lower ex-
pressed miR-625 was related to the proliferation and invasion of
EC cell lines in vitro. We demonstrated direct binding of miR-625
to the Sox2 30 UTR and showed that miR-625 overexpression
diminished but miR-625 knockdown increased Sox2 expression
levels in EC cells, indicating that miR-625 was related to prolifera-
tion and invasion of EC by regulating Sox2.
In summary, we identiﬁed the inverse expression levels of miR-
625 and Sox2 in our 158 EC cases, both of which were related to
tumor depth, stage and metastasis. We also provided evidence to
prove the regulatory function of miR-625 on Sox2 by direct binding
of its 30 UTR. As the limit on the number of EC samples and cell
types, more elaborate studies will be necessary for further explora-
tion of the potential role of miR-625 in development of EC. In fu-
ture, miR-625-Sox2 pathway that we studied might be exploited
in a therapeutic approach for the treatment of EC.
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